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Abstract A limitation in traditional stepwise population
pharmacokinetic model building is the difficulty in han-
dling interactions between model components. To address
this issue, a method was previously introduced which
couples NONMEM parameter estimation and model fitness
evaluation to a single-objective, hybrid genetic algorithm
for global optimization of the model structure. In this
study, the generalizability of this approach for pharmaco-
kinetic model building is evaluated by comparing (1) cor-
rect and spurious covariate relationships in a simulated
dataset resulting from automated stepwise covariate mod-
eling, Lasso methods, and single-objective hybrid genetic
algorithm approaches to covariate identification and (2)
information criteria values, model structures, convergence,
and model parameter values resulting from manual step-
wise versus single-objective, hybrid genetic algorithm
approaches to model building for seven compounds. Both
manual stepwise and single-objective, hybrid genetic
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algorithm approaches to model building were applied,
blinded to the results of the other approach, for selection of
the compartment structure as well as inclusion and model
form of inter-individual and inter-occasion variability,
residual error, and covariates from a common set of model
options. For the simulated dataset, stepwise covariate
modeling identified three of four true covariates and two
spurious covariates; Lasso identified two of four true and 0
spurious covariates; and the single-objective, hybrid
genetic algorithm identified three of four true covariates
and one spurious covariate. For the clinical datasets, the
Akaike information criterion was a median of 22.3 points
lower (range of 470.5 point decrease to 0.1 point decrease)
for the best single-objective hybrid genetic-algorithm
candidate model versus the final manual stepwise model:
the Akaike information criterion was lower by greater than
10 points for four compounds and differed by less than 10
points for three compounds. The root mean squared error
and absolute mean prediction error of the best single-
objective hybrid genetic algorithm candidates were a
median of 0.2 points higher (range of 38.9 point decrease to
27.3 point increase) and 0.02 points lower (range of 0.98
point decrease to 0.74 point increase), respectively, than
that of the final stepwise models. In addition, the best
single-objective, hybrid genetic algorithm candidate mod-
els had successful convergence and covariance steps for
each compound, used the same compartment structure as
the manual stepwise approach for 6 of 7 (86 %) com-
pounds, and identified 54 % (7 of 13) of covariates inclu-
ded by the manual stepwise approach and 16 covariate
relationships not included by manual stepwise models. The
model parameter values between the final manual stepwise
and best single-objective, hybrid genetic algorithm models
differed by a median of 26.7 % (q1 = 4.9 % and
q3 = 57.1 %). Finally, the single-objective, hybrid genetic
algorithm approach was able to identify models capable of
estimating absorption rate parameters for four compounds
that the manual stepwise approach did not identify. The
single-objective, hybrid genetic algorithm represents a
general pharmacokinetic model building methodology
whose ability to rapidly search the feasible solution space
leads to nearly equivalent or superior model fits to phar-
macokinetic data.
Keywords Pharmacokinetics  Model building  Genetic
algorithms
Introduction and background
Two key objectives in population pharmacokinetic model
building, removing systematic errors (bias) and minimizing
the amount of unexplained variance between the experi-
mental data and the model predictions, are accomplished by
selecting an appropriate model structure, identifying fixed
and random effects, and including characteristics of indi-
viduals (covariates) in the model. Decisions regarding
specifics of the model structure are commonly made in
series to isolate a potential model component (e.g., addi-
tional compartment, covariate relationship) and evaluate
the effect, an algorithm referred to as stepwise regression
[1]. For example, in the stepwise forward/backward
approach to model building, the model structure (e.g.,
number of compartments, presence of an absorption lag
time, etc.) is selected, the inter-individual variability and
residual error structures are chosen, and then the effect of
either adding an individual covariate to the base model
(forward addition) or removing an individual covariate from
a model which includes all included covariates (backward
elimination) is evaluated. However, covariates may become
relevant (or irrelevant) in combination and the inclusion of
covariates and error terms can affect the fit characteristics of
the compartment model [2]. Such higher order interactions
are often difficult to identify because the number of possible
combinations of model decisions is prohibitive (although
skilled pharmacokinetic modelers may be able to identify
some higher order interactions through diagnostic plots,
personal experiences, or understanding of the biology and
pharmacology) without the use of combinatoric optimiza-
tion techniques. Bies et al. [3] discussed the suitability of
various multi-variable optimization methods to pharmaco-
kinetic model covariate and structure decision making
before selecting a single-objective, hybrid genetic algo-
rithm (SOHGA) based modeling building method, coupling
the SOHGA to NONMEM for parameter estimation, and
demonstrating its application on pharmacokinetic data for a
single compound. In the paper by Bies et al. [3], the SOHGA
resulted in a best-fit candidate model with the same com-
partmental structure as the stepwise method but with a
statistically better fit to the data, additional covariates, and
lower between patient variability. In this manuscript the use
of SOHGA for pharmacokinetic model building is evalu-
ated by comparing the selection of covariates and model
parameter estimates using automated stepwise covariate
selection, Lasso, and SOHGA for a simulated dataset and
fits to plasma concentration data for the final models
selected by these manual stepwise versus SOHGA approa-
ches for each of seven, prospectively identified, compounds.
In addition, we compare the final model structure, com-
pletion of model convergence and covariance steps, inclu-
sion of inter-individual and inter-occasion variability,
covariates included, and percent difference in the pharma-
cokinetic model parameters between the two model build-
ing approaches to clinical data.
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Genetic algorithms
Genetic algorithms are a class of global search techniques
commonly used in engineering and science for multi-vari-
able parameter estimation; this tool has been successfully
applied to problems such as to electrical distribution [4],
biological networks [5], and scheduling processes [6]. Per-
haps more remarkably, and relevant to this application, a
genetic algorithm method was able to derive laws of nature
without any prior knowledge of physics or geometry, based
solely on observed data [7]. The name ‘‘genetic algorithm’’
refers to the method’s operators which mimic the processes
of biological natural selection. A basic genetic algorithm
maintains a finite pool of candidate models which ‘‘evolve’’
from generation to generation by applying operators that
‘‘mate’’ and ‘‘mutate’’ candidate models of the current gen-
eration to form a new generation of candidate models (see
Goldberg [8] for details on genetic algorithm implementa-
tion). These mating, or cross-over, and mutation operators
require that models are represented in binary notation where
bit strings coding for individual model features are concat-
enated to form a model string. In the cross-over operator, two
‘‘parent’’ models are selected and the first N number of bits
swapped to form two offspring models where N is a uniform
random distribution of the number of bits in the genome
string. The mate selection is not an entirely random as most
genetic algorithms weight a candidate model’s mating like-
lihood by the model’s performance. This implies that can-
didate models with advantageous qualities (e.g., low value
for -2 9 log likelihood, more parsimonious, successful
convergence, etc.) are more likely to be involved in mating,
those qualities are more likely to be seen, perhaps multiple
times, in the next generation of candidate models, and can-
didate models in subsequent generations tend to have better
performance. The mutation operator randomly changes a
binary bit within a candidate model which can lead to further
exploration of the solution space and advanced techniques
such as niching and elitism keep the candidates from col-
lapsing into a single region and keep the best performing
candidate models intact between generations, respectively.
Although convergence to the global optimum is not guar-
anteed, properly applied genetic algorithms have been
shown to be quite robust, with only very irregular and
complex solution spaces being ‘‘GA deceptive’’ [8].
Single-objective genetic algorithms
The ‘‘single-objective’’ approach uses a single outcome as
a measure of a candidate model’s fitness. While this fitness
can be based on a single objective, frequently multiple
objectives (e.g., -2 9 log likelihood, parsimony, conver-
gence, covariance, correlation, eigenvalues, etc.) are com-
bined into a single, composite outcome measure using user
defined weights. New approaches can be used to simulta-
neously optimize on multiple objectives [9].
Hybrid genetic algorithms
While simple genetic algorithms are efficient at identifying
‘‘good’’ regions of the solution space, they are inefficient at
identifying a locally optimal solution within a ‘‘good’’
region of the search space. This is because, although the
cross over operator is effective at identifying generally
good regions of solution space, identifying the local optima
is limited by the rate of mutation, a relatively low fre-
quency event. As such, a hybrid approach is one that
complements the globally-oriented genetic algorithm with
a local search method to refine candidate model selection.
For example, in Bies et al. [3] a simple genetic algo-
rithm was interrupted every fifth generation by a simple
downhill local search method. In the simple downhill
search, the fitness of a candidate model is compared with
all models whose strings differ by a single bit and the best
model replaces the original candidate model as a candidate
model. This process is repeated until no further improve-
ment is seen. At this point, the genetic algorithm is
resumed, with the new best candidate models.
Application of a single-objective, hybrid genetic-
algorithm to pharmacokinetic model building
Bies et al. [3] applied the SOHGA framework to pharma-
cokinetic model building by mapping pharmacokinetic
model decision outcomes to binary strings in such a way that
the binary string for each outcome of a given decision is
unique. The strings corresponding to individual model
decisions (e.g. 1 vs. 2 compartments, with or without lag
time, initial estimate for Volume of 10 vs. 100 L) are con-
catenated to form the model string whose particular binary
values define a candidate model structure. That is, each
model decision is contained in a binary string segment with a
conserved initiation and termination location within model
strings. The binary pattern uniquely specifies the outcome for
that model decision and the collection of all model decision
outcomes for a particular model string specifies a candidate
model. The SOHGA methodology was then applied by
building a set of candidate models, running each in NON-
MEM to estimate the model parameters, describing the fit-
ness of candidate models with a single objective function
value, and performing hybrid, genetic algorithm operations.
Methods
We took two approaches to assess the application of
SOHGA for pharmacokinetic model selection. The first
J Pharmacokinet Pharmacodyn (2012) 39:393–414 395
123
approach was to fit pharmacokinetic models to longitudinal
drug concentration data simulated using known population
parameters and covariate effects. The second approach was
to fit pharmacokinetic models to longitudinal drug con-
centration data from clinical trials for each of seven com-
pounds: intravenous administration of citalopram and
17-(dimethylaminoethylamio)-17-demethoxygeldanamycin
(DMAG) and oral dosing of escitalopram, olanzapine,
perphenazine, risperidone, and ziprasidone.
For the simulated dataset, only covariate identification
was tested. That is, the compartment structure, inter-indi-
vidual and residual error structures were fixed as the ‘‘true’’
model. Three automated modeling building approaches
were implemented: stepwise covariate modeling (SCM)
[10], Lasso [11], and SOHGA. We tested three automated
SCM forward inclusion/backward elimination p value cri-
teria (0.05, 0.05; 0.05, 0.01; and 0.10, 0.01) and two SO-
HGA methods with 3.84 and 10 point penalties per
parameter. Each model approach was evaluated based on
‘‘true’’ and spurious covariates identified and the objective
function value.
To build the pharmacokinetic models for the clinical
compounds, two different model building approaches were
tested: a manual method (implemented by an experienced
NONMEM user) using stepwise forward inclusion/back-
ward elimination for covariate selection and a single-
objective, hybrid genetic algorithm. Both modeling
approaches made decisions on covariate inclusion as well as
functional forms of the covariate relationships, inter-indi-
vidual variability, and residual error. The quality of best
fitting models identified using the stepwise and hybrid
genetic algorithm model development approaches were then
compared for each compound. In addition, the covariates
included, the precision of model parameters, and the com-
pleteness of the searches are reported. Each modeling
approach was performed blinded to the results of the other
approach.
Simulated dataset
The simulated data was created with two objectives in
mind: (1) a highly identifiable model and (2) realistically
high correlations between covariates. Data were simulated
for 200 subjects given a single, intravenous dose using the
ADVAN1/TRANS2 subroutine in NONMEM 7.2. Sample
times were 0.25, 0.5, 1, 2, 3, 6, 10, and 24 h after the dose.
We created realistically correlated covariates (Table 1).
First, the uncorrelated covariates were simulated. These
were body-mass index (BMI), sex, creatinine (CR), and
age. Next, dependent covariates were simulated. These
were height (HT) as a function of sex, weight (WT) as a
function of body-mass index and height, body-surface area
(BSA) as a function of height and weight [12], and creat-
inine clearance (CRCL) as a function of weight, age, cre-
atinine, and sex [13]. In addition to the covariates described
above that directly or indirectly entered into the model,
four unrelated or ‘‘spurious’’ covariates (CV1 to CV4) were
included. The correlation matrix for the simulated covari-
ates and NONMEM code for generating the simulated
dataset is given in Appendix A.
The simulated data contained exponential effects of
body-mass index and creatinine clearance on clearance,
exponential effects of body-surface area and sex on volume
of distribution, lognormal inter-individual effects on both
Table 1 Distribution characteristics of covariates used for simulated dataset
Covariate Source Mean, expected (observed) Standard deviation,
expected (observed)
Body mass index (BMI) Log normal 26.0 kg/m2 (26.3) 0.15 kg/m2 (0.156)
Sex (SEX) Discreet (0,1) – 0.5 males, 0.5 females
(0.47 males, 0.53 females)
Age (AGE) Normal 40 years (38.8 years) 8 years (8.18 years)
Creatinine (CR) Log normal 1.0 mg/Dl (0.98 mg/Dl) 0.13 mg/DI (0.12 mg/DI)
Height (HT) Mean of 1.7 for males,
1.5 for females
1.6 m (1.59 m) 0.2 m
Weighta (WT) BMI 9 HT2 67.4 kg 21.2 kg
Body-surface areaa (BSA)
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
HT  100  WT=3600p 1.71 m2 0.363 m2
Creatinine clearancea (CRCL) (140 9 AGE) 9 WT/(72 9 CR) 98 mL/min 36 mL/min
Unrelated covariate 1 (CV1) Log normal 100 (97.3) 0.3 (0.31)
Unrelated covariate 2 (CV2) Log normal 10 (10.1) 0.4 (0.42)
Unrelated covariate 3 (CV3) Log normal 1.0 (0.99) 0.2 (0.21)
Unrelated covariate 4 (CV4) Log normal 0.1 (0.096) 0.2 (0.21)
a There is no expected mean or expected standard deviation for calculated covariates
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clearance and volume of distribution, and a combined
residual error structure. The magnitude of the covariate
effect was selected to provide a range of effects on the
NONMEM objective function values (between 10 and 100
points for each covariate inclusion) seen in analysis of real
data.
The clearance and volume of distribution were set to
generate data over a 24 h sampling period that would
permit their estimation. The baseline clearance was
0.763 L/h and the baseline volume of distribution was
1.94 L. These baseline values give an expected half-life of
1.76 h. This resulted in data for at least 3 elimination half-
lives for the vast majority of simulated subjects.
Clinical datasets
The study was approved by the Indiana University Insti-
tutional Review Board. The study protocols for data col-
lection were approved by the Institutional Review Boards
at the respective institutions and all patients, or his or her
legal guardian, provided informed consent.
Individuals who received oral olanzapine [14], perp-
haenazine [15], risperidone [16], or ziprasidone [17] were
patients treated between January 2001 and December
2004 as part of the Clinical Antipsychotic Trials of
Intervention Effectiveness (CATIE)—a multisite, US
study of randomized, double-blind, medication compara-
tive-effectiveness trial—in the treatment of Alzheimer’s
(CATIE-AD) and schizophrenia (CATIE-SZ). Details of
the inclusion, exclusion, and study design can be found in
Stroup et al. [18] for the schizophrenia studies and
Schneider et al. [19] for Alzheimer’s studies with a
summary of the treatment protocol and final enrollment
statistics shown in Table 2. Individuals who received oral
escitalopram were patients treated for major depression as
part of the clinical trial ‘‘Depression: The Search for
Treatment Relevant Phenotypes’’ [20, 21]. Individuals
who received intravenous citalopram were part of a cross
sectional study of healthy volunteers participating in
Pittsburgh’s Adult and Human Behavior Project; these
individuals were between the ages of 30 and 55 years and
not taking medications for hypertension, lipid disorders,
or diabetes [22]. Individuals who received intravenous
DMAG were cancer patients either at Pittsburgh’s Cancer
Institute or at Memorial Sloan-Kettering participating in a
phase II study.
Table 2 Sample sizes and treatment protocols
Compound Number of patients Number of concentration
measurements
Treatment protocol
Citalopram, IV [22] 331a 1,324 0.33 mg/kg lean body mass
infusion over 30 minb
DMAG, IV 67 (48 Pittsburgh, 19 MSK) 1,148 (1,000 Pittsburgh, 148 MSK) Median of 36.0 mg/m2 (range
from 2.5 to 160.1 mg/m2)c
Escitalopram, oral [21] 172 (105 Pittsburgh, 67 Pisa) 473 (320 Pittsburgh, 153 Pisa) 5–20 mg/day, 19/dayd
Olanzapine, oral [14] 523 (117 AD, 406 SZ) 1,527 (200 AD, 1,327 SZ) AD: 2.5–20 mg/day, 19/daye
SZ: 7.5–30 mg/day, 1–29/dayf
Perphenazine, oral [15] 156 (all SZ) 421 (all SZ) AD: Not applicablee
SZ: 8–32 mg/day, 1–29/dayf
Risperidone, oral [16] 490 (110 AD, 380 SZ) 1,236 (168 AD, 1,068 SZ) AD: 0.5–6 mg/day, 1–29/daye
SZ: 1.5–6 mg/day, 1–29/dayf
Ziprasidone, oral [17] 233 (all SZ) 568 AD: Not applicablee
SZ: 40–160 mg/dayf
a Three patients excluded from analysis by Muldoon et al. [18] (two patients because of missing citalopram measurements and one patient with
an outlier prolactin response) were retained in the current dataset
b Blood samples for citalopram concentration measurement were drawn at 30, 45, 90, and 150 min [18]
c Patients at Memorial Sloan-Kettering (MSK) received a single infusion and the DMAG concentration was measured at 0, 0.5, 0.93, 1.5, 2, 4, 6,
24, and 48 h after the infusion was started. Patients at the Pittsburgh Cancer Institute received either 3 infusions (at 0, 25, and 49 h) or 5 infusion
(with additional infusions at 73 and 97 h) and the DMAG concentration was measured at the start of each infusion as well as 0.5, 0.92, 1.08, 1.17
1.25, 1.5, 2, 3, 5, 13, and 17 h after the start of the first, third, and fifth infusions
d Patients were treated for a minimum of 32 weeks with blood samples collected at weeks 4, 12, 24, and 36 [16]
e Alzheimer’s (AD) patients were treated for 12 weeks with blood plasma drawn at weeks 2, 4, and 12 as well as when medication was switched.
The mediation could be switched at week 2 (and the 12 week treatment period begins anew) if it was ineffective or induced side-effects
f Schizophrenia (SZ) patients were treated for 18 months with blood samples collected every three months. Patients with an initial treatment
failure were offered a choice between open-label treatment or re-randomization
J Pharmacokinet Pharmacodyn (2012) 39:393–414 397
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Manual stepwise forward inclusion/backward
elimination approach for modeling clinical datasets
Manual stepwise model results were taken from the liter-
ature [14–17, 21] or were generated from unpublished data
(DMAG) or data reported elsewhere in the literature [22].
These models were determined using similar methods.
Briefly, for each compound, a covariate free model was
used to select the model compartment structure with the
combination of inter-individual and residual variability
structures resulting in the lowest objective function value
calculated by NONMEM (twice the negative log likelihood
plus a fixed constant offset) and a reasonable distribution of
residuals as the base model.
Univariate evaluations of covariates were then per-
formed. Initially, each covariate was included individually
in the base model and individual predicted values were
calculated using either first-order (risperidone only) or first-
order conditional estimation with interaction using Xpose
[23] for all possible covariates and function forms. The
covariate and its function form that (1) yielded the lowest
objective function conditional on (2) improved the objec-
tive function value by at least 3.84 (citalopram, DMAG,
and [14, 15, 17, 21]) or 7.88 [16] points compared to the
base model (which corresponds to Chi-squared values of
p = 0.05 and p = 0.005 with one degree of freedom,
respectively) and (3) in which there appeared to be a
graphical relationship between the deviation in an indi-
vidual predicted value and the covariate value across
individual predicted values was included in the model. The
remaining covariates were then included individually in the
updated model, the inclusion criteria evaluated, and the
model sequentially updated with additional covariates until
no further covariates met the model inclusion criteria.
Finally, individual covariates were removed from the
final model and the change in the objective function was
calculated. Covariates were excluded from the final model
if, when the covariate was removed, the objective function
value increased by less than 3.84 (citalopram, DMAG, [14,
15, 21]), 6.63 [17] (a Chi-squared value of p = 0.01 with
one degree of freedom), or 7.88 [16]. Although the models
were derived using different versions of NONMEM, the
final models reported in the literature were re-run in
NONMEM VI, Level 1.0 using Fortran G77 and NON-
MEM VII, version 7.2 with Intel Fortran to confirm that the
results were independent of the NONMEM version.
Single-objective, hybrid genetic algorithm approach
The SOHGA operates on a set of candidate models in
which each candidate specifies covariates included the in
model, their functional forms, the structure of the inter-
individual and residual variability, and the initial
pharmacokinetic model parameter estimates [3]. Special-
use software in which the SOHGA, coded and run in
Microsoft Visual Studio and Compaq Digital Fortran,
creates NONMEM control files to fit parameters and cal-
culate the fitness of candidate models using NONMEM VI,
Level 1.0 or NONMEM VII, version 7.2 using either first-
order (risperidone only) or first-order conditional estima-
tion with interaction using Xpose [23]. The fitness function
for a candidate model was its objective function value plus
a parsimony penalty of 10 points for each covariate,
residual error, and inter-individual error parameter; a 400
unit penalty if the minimization itself or the covariance
matrix did not converge; and a 300 unit penalty if any of
the absolute values of the off-diagonal elements of the
estimation correlation matrix were [0.95. These penalties
are outlined in Bies et al. [3] although the 300 unit penalty
if the ratio of the largest to smallest eigenvalues, or the
condition number, was [1,000 was not implemented
because condition numbers were not considered during
the manual searches. For compounds in which the best
SOHGA candidate had a condition number [1,000, we
performed a post hoc SOHGA analysis that included the
condition number penalty.
The SOHGA retained a population of 200–400 candi-
date models for 30–50 generations. A total of 0.7 crossover
events were expected per set of parents. Candidate models
for crossover were randomly selected based on scaled fit-
ness function values; linear regression was performed using
all fitness functions within two standard deviations of the
mean, the fitness of the regression values were scaled to
between 0.2 and 4, and outlying values were assigned one
of these extreme values. This scaling of the fitness function
improves convergence by not permitting outliers to domi-
nate the selection process. The mutation rate was 0.01
mutations per bit. The candidate model with best fitness
function was retained to the next generation, a technique
known as elitism. Niche evaluation (where a niches differ
by\4 bits) was performed. In niche evaluation, a penalty is
applied to models that are similar to other models (differ by
4 or fewer bits). This prevents early convergence, main-
taining diversity in the population. Four niches were used,
insuring that at least four regions of the search space were
explored in each phase of the search. A simple downhill
search was performed every five generations. In the
downhill search, each bit of the best model in each niche in
reversed (0 to 1, 1 to 0) and the resulting models run. For
example, if the bit string if of length 40, the downhill
search will generate 40 new models for each niche that
each differ by a single bit. If any of the resulting models are
better than the current best model for that niche, the pro-
cess is repeated with that model, until no further
improvement is seen. Finally, timeout conditions were set
where NONMEM timed out (terminated without
398 J Pharmacokinet Pharmacodyn (2012) 39:393–414
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completion failing convergence) after up to 600 min for a
model and a generation timed out after up to 6,000 min
although the exact timeout conditions varied by compound.
Pharmacokinetic model structures for modeling clinical
datasets
Only pharmacokinetic model structures considered in the
stepwise approach for modeling a compound were options
for the SOHGA approach for that compound (see Table 3).
This was done to isolate the search part of the model
selection process; there was no intent to reproduce the
hypothesis generation part of the process. In addition, in a
secondary analysis, the SOHGA approach was applied to
the risperidone dataset using FOCE with interaction. This
was done to determine whether the SOHGA approach
could identify a model that successfully converges for a
scenario in which the stepwise approach did not.
In addition to the structure, the initial values of the
parameter estimates (and acceptable minimum and maxi-
mum values) must be specified. The SOHGA methods
treats the combination of model structure and initial esti-
mates as a single entity so multiple initial parameter values
for the same model structure can be considered resulting in
a search on initial estimates for parameters as well as the
model structure.
Functional forms of covariate relationships, inter-
individual variability, and residual error variability
for modeling clinical datasets
The stepwise method and SOHGA were each used to make
decisions regarding model compartment structure,
Table 3 Model structure and covariate options for the stepwise and single-objective, hybrid genetic algorithm model building approaches
Compound NONMEM model structures
testeda,b
First-order (FO) or
first-order conditional
(FOCE) estimation
Covariates analyzedc
Citalopram, IV ADVAN3, TRANS4 FOCE with interaction Continuous: age, body-mass index, fat mass,
fat-free mass, weight
Discrete: sex
DMAG, IV ADVAN3, TRANS4 FOCE with interaction Continuous: age, albumin, alanine
aminotransferase, aspartate transaminase,
bilirubin, blood urea nitrogen, body surface
area, creatinine, weight
ADVAN11, TRANS4
(And possible inter-occasion
variability on clearance, central
volume, and first inter-
compartment clearance)
Discrete: sex
Escitalopram, oral [21] ADVAN2, TRANS2 FOCE with interaction Continuous: age, body-mass index, weight
ADVAN4, TRANS4 Discrete: clinical site, CYP2C19 genotype,
race, sex
Olanzapine, oral [14] ADVAN2, TRANS2 FOCE with interaction Continuous: age
ADVAN4, TRANS4 Discrete: race, sex, smoking status
Perphenazine, oral [15] ADVAN2, TRANS2 FOCE with interaction Continuous: age, number of cigarettes per
day, weightADVAN4, TRANS4
Discrete: race, sex, smoking status,
concomitant medication use
Risperidone, oral [16] ADVAN2, TRANS2 FO Continuous: age, weight
ADVAN4, TRANS4 Discrete: race, sex, smoking status,
concomitant medication use(And 1, 2, or 3 clearance
subpopulations)
Ziprasidone, oral [17] ADVAN2, TRANS2 FOCE with interaction Continuous: age, height, number of cigarettes
per day, weight
Discrete: race, sex, smoking status,
concomitant medication use
a ADVAN2 is a one-compartment linear model with first order absorption, ADVAN3 is a two compartment linear model; ADVAN4 is a two
compartment linear model with first order absorption; and ADVAN11 is a three compartment linear model
b TRANS2 with ADVAN2 specifies model options for clearance (CL) and volume of distribution (V); TRANS4 with ADVAN3 or ADVAN4
specifies model options for CL, central volume (V1), inter-compartment clearance (Q), and peripheral volume (V2); and TRANS4 with
ADVAN11 specifies model options for CL, V1, first inter-compartment clearance (Q1), V2, second inter-compartment clearance (Q2), and third
compartment volume (V3)
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covariate inclusion as well as functional form of the
covariate relationships, inter-individual variability, and
residual error variability. Only function forms considered
in the stepwise approach for modeling a compound were
options for the SOHGA approach for that compound (see
Table 4). Continuous covariate relationships included: no
relationship, additive (add), proportional (prop), exponen-
tial (exp), power-law (pow), or Michaelis–Menten (MM).
Discrete covariate relationships included: no relationship,
additive, proportional, or exponential. The typical value of
Table 4 Covariate, inter-individual variability, and residual error relationships considered during model building
Mathematical function Compounds tested
Covariate relationshipa
Continuous covariate
No relationship TVCLi ¼ TVCLi Citalopram, DMAG, Escitalopram, Olanzapine, Perphenazine,
Risperidone, Ziprasidone
Additive TVCLi ¼ TVZi þ xi;j  exj
 
hðaddÞj Citalopram, DMAG, Olanzapine, Perphenazine
Proportional
TVCLi ¼ TVCLi 1 þ hðpropÞj xi;j
exj
 
Citalopram, DMAG, Escitalopram, Olanzapine
Exponential
TVCLi ¼ TVCLiexp xi;j
exj
hðexpÞj
 
Citalopram, DMAG, Escitalopram, Perphenazine, Risperidone,
Olanzapine, Ziprasidone
Power-law
TVCLi ¼ TVCLi xi;j
exj
 hðpowÞj Citalopram, Escitalopram, Olanzapine, Perphenazine
Michaelis–Menten
TVCLi ¼ TVCLi
hðMMÞ
j;1
xi;j
exj
 
hðMMÞ
j;2
þ xi;j
exj
 
DMAG
Discrete
No relationship TVCLi ¼ TVCLi Citalopram, DMAG, Escitalopram, Olanzapine, Perphenazine,
Risperidone, Ziprasidone
Additive TVCLi ¼ TVCLi þ
P
k¼2
d k  xjji
 
hðaddÞj;k Citalopram, DMAG, Escitalopram, Olanzapine, Perphenazine,
Ziprasidone
Proportional
TVCLi ¼ TVCLi 1 þ
P
k¼2
d k  xjji
 
hðpropÞj;k
 
Perphenazine
Exponential
TVCLi ¼ TVCLiexp
P
k¼2
d k  xjji
 
hðexpÞj;k
 
Risperidone, Perphenazine
Type of inter-individual
variabilityb
No relationship CLi ¼ TVCLi Citalopram, DMAG, Escitalopram, Olanzapine, Perphenazine,
Risperidone, Ziprasidone
Exponential CLi ¼ TVCLi; exp gðCLÞi
 
Citalopram, DMAG,Escitalopram, Olanzapine, Perphenazine,
Risperidone, Ziprasidone
Type of residual
variabilityc
Additive Yi;j ¼ Fi;j þ eð1Þi;j Citalopram, DMAG, Escitalopram, Olanzapine, Perphenazine,
Risperidone, Ziprasidone
Proportional Yi;j ¼ Fi;j þ 1 þ eð1Þi;j
 
Citalopram, DMAG, Escitalopram, Olanzapine, Perphenazine,
Risperidone, Ziprasidone
Combined additive and
proportional
Yi;j ¼ Fi;j 1 þ eð1Þi;j
 
þ eð2Þi;j Citalopram, DMAG, Escitalopram, Olanzapine, Perphenazine,
Risperidone, Ziprasidone
a Modification of a typical value for the example of clearance of the ith individual by the jth covariate or where xi,j is the value of the jth
covariate for the ith patient, exj is the median value of the jth covariate, xjji is the category (counting) number of the jth covariate for the ith
patient, and hðnÞj is a parameter for functional form n that describe the relationship of the jth covariate
b Inter-individual function forms considered for the example of the clearance of the ith individual. The g CLð Þ takes a standard normal distribution
with standard deviation xðCLÞ
c Residual variability function forms considered. The variable Yi,j is the jth observation for the ith patient, Fi,j is the corresponding model
prediction, and eð1Þi;j and e
ð2Þ
i;j take standard normal distributions with variances r
2
1 and r
2
2, respectively
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the pharmacokinetic model parameters were calculated by
sequentially incorporating the effects of the individual
covariate relationships for a patient with a given set of
continuous and discrete covariates beginning with a
covariate free typical value. The model variable value
without covariates as well as the covariate function forms
and corresponding parameters were included in the model
fits to data. Covariates considered for inclusion by the
model are listed in Table 3. All continuous covariates were
centered at zero.
Two inter-individual variability function forms were
considered: no inter-individual variability and exponential
(see Table 4). These functions operated on random effects
which were assumed to follow normal distributions cen-
tered at zero with the standard deviations included in the
model fit to data.
Three residual variability function forms were consid-
ered: additive, proportional, and combined additive and
proportional (see Table 4). These functions operated on
random effects that were assumed to follow normal dis-
tributions centered at zero with variances included in the
model fit to data.
Model evaluation
Six measures were used for model evaluations and com-
parisons: the pharmacokinetic objective function value
(OBV), the SOHGA fitness function, Akaike information
criterion (AIC), Bayesian information criterion (BIC),
mean prediction error (MPE), and root mean squared error
(RMSE).
The pharmacokinetic objective function was used in the
stepwise approach for covariate, inter-individual error, and
residual error term inclusion/elimination. The pharmaco-
kinetic objective function is calculated by NONMEM and
is twice the negative log likelihood plus a fixed constant
offset. Statistical differences in models were determined
using Chi-squared distribution with one degree of freedom.
The SOHGA fitness function was used to compare
candidate models in the genetic algorithm. The SOHGA
fitness function was the summation of objective function
value plus penalty terms for decreased parsimony (separate
terms for fixed effect terms or ‘‘THETA’’s, inter-individual
variability terms or ‘‘OMEGA’’s, and residual error terms
or ‘‘SIGMA’’s), lack of convergence, failing covariance
step, and failing the correlation test.
The AIC and BIC were used to compare the fitness of
models obtained using the stepwise approach with those of
the genetic algorithms. The AIC ¼ 2k  OBV and BIC ¼
klog nð Þ þ OBV where k is the number of model parameters
and n is the number of data points.
The mean prediction error for each compound is
MPE ¼ 1
N
X
N
i¼1
IPREDi  DVið Þ
and the root mean squared error is
RMSE ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1
N
X
N
i¼1
IPREDi  DVið Þ2
v
u
u
t ;
where N is the total number of concentration measure-
ments, DVi is the measured concentration, and IPREDi is
the individual concentration prediction for the ith
measurement.
Determination of outcomes
The primary outcome, comparing the quality of best
pharmacokinetic model fits for the stepwise and single-
objective hybrid genetic algorithm methods to clinical data,
was quantified by the difference in AIC between the
stepwise and single-objective, hybrid genetic algorithm
approaches. The prediction error was also assessed by the
median difference in the absolute MPE and RMSE between
final stepwise models and best SOHGA candidates. In a
secondary analysis, model compartment structure and the
success of the model convergence and covariance steps
was determined from the NONMEM control and output
files, respectively. In another secondary analysis, the
agreement in including covariates and variability terms on
model parameters between the final stepwise model and the
SOHGA candidate model with the lowest AIC was mea-
sured using a kappa analysis (a statistical measure of inter-
method agreement for classification) [24]. The median
percent difference in the model parameter values between
the stepwise and SOHGA models was calculated, for
variables common between the two models, using the
absolute differences with the stepwise model variable
values as the reference.
Results
Models for simulated dataset
As shown in Table 5, all automated SCM, Lasso, SOHGA
options examined correctly identified that body-mass index
and creatinine clearance influence clearance. All automated
SCM and SOHGA options correctly identified the gender
effect on central volume but this covariate was not iden-
tified by Lasso. All automated SCM, Lasso, and SOHGA
options failed to identify the effect of body surface area on
central volume. All automated SCM options identified
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spurious height and an unrelated covariate effect on the
volume of distribution. In addition, the SCM option with
the less stringent backwards elimination criteria (p = 0.05
vs. 0.01 for other automated SCM options) identified a
spurious weight covariate effect on clearance. No spurious
covariate effects were identified by any of the Lasso
method options. The SOHGA option with the 3.84 point
penalty identified 3 spurious covariates and 1 of these
spurious covariates was also identified by the SOHGA
model with a 10 point penalty per parameter.
As shown in Table 6, the typical values of clearance for
the SCM (0.01, 0.01), unconstrained Lasso, and SOHGA
with a 10 point per covariate penalty were 0.614, 0.704,
and 0.672 L/h while the true value was 0.763 L/h and the
Table 5 True and spurious covariate relationships identified in the simulated data by the automated stepwise covariate modeling, Lasso, and
SOHGA approaches and the models fit characteristics
Method ‘‘True’’ covariates Spurious covariates Objective
function value
Clearance Volume of distribution Clearance Volume
of distribution
Original model BMI, CRCL BSA, Sex – – 6101.2
Stepwise covariate modeling (SCM):
p value for inclusion,
p value for elimination
0.05, 0.05 BMI, CRCL Sex WT HT, CV1 6085.9
0.05, 0.01 BMI, CRCL Sex – HT, CV1 6091.1
0.10, 0.01 BMI, CRCL Sex – HT, CV1 6091.1
Lasso model BMI, CRCL – – – 6254.2
Single-objective, hybrid genetic algorithm
3.84 point penalty per parameter BMI, CRCL Sex BSA HT, CV1 6086.7
10 point penalty per parameter BMI, CRCL Sex – HT 6097.9
BMI body mass index, BSA body surface area, CRCL creatinine clearance, CV1 unrelated covariate 1, HT height, WT weight
Table 6 Effects of covariates on clearance and volume of distribution
Method Typical parameter value (relative
standard error)
Inter-individual variability (relative
standard error)
Residual error
Clearance (L/h)
– TVCL (%)
Volume of
distribution (L) –
TVV (%)
Clearance (L/h)
– TVCL (%)
Volume of
distribution (L) –
TVV (%)
Additive
component
(%)
Proportional
component (%)
True model 0.763 1.94 20.0 % 20.0 % 0.001 0.01
Automated stepwise covariate modeling: p value for inclusion, p value for elimination
0.05, 0.05 0.612 (3.1) 1.64 (5.7) 16.7 (10.3) 23.4 (9.5) 6.32E-4
(15.4)
0.0944 (4.2)
0.05, 0.01 0.614 (3.1) 1.66 (5.6) 17.1 (10.4) 23.4 (9.5) 6.32E-4
(15.6)
0.0944 (4.2)
0.10, 0.01 0.614 (3.1) 1.66 (5.6) 17.1 (10.4) 23.4 (9.5) 6.32E-4
(15.6)
0.0944 (4.2)
Lasso modela 0.662 (NA) 1.88 (NA) 32.5 (NA) 30.6 (NA) 6.29E-4 (NA) 0.0946 (NA)
Single-objective, hybrid genetic algorithm
3.84 point penalty
per parameter
0.681 (3.1) 2.21 (5.0) 16.7 (10.0) 23.6 (9.4) 6.31E-4
(15.4)
0.0944 (4.2)
10 point penalty
per parameter
0.672 (3.1) 2.17 (5.3) 17.1 (10.4) 24.2 (9.1) 6.32E-4
(15.5)
0.0944 (4.2)
a Relative standard errors denoted by ‘‘NA’’ are not available because the covariance matrix did not converge
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typical values of volume of distribution were 1.66, 1.87,
and 2.17 while the true value was 1.94 L.
Models for clinical datasets, primary outcome—Akaike
information criterion
The AIC value did not increase (or worsen) by more than
10 points for the hybrid genetic algorithm model versus the
stepwise model for all 7 compounds (see Table 7). Of
these, there were greater than 10 point improvements in
the AIC with the hybrid genetic algorithm versus the step-
wise approach for four compounds—citalopram (-22.3),
DMAG (-22.3), olanzapine (-470.5), and risperidone
(-278.1)—and minimal AIC changes for escitalopram
(-0.1), perphenazine (-4.8), and ziprasidone (-4.5).
Models for clinical datasets, Secondary outcomes—bias
and precision
The RMSE of the best SOHGA candidate was a median of
0.2 points higher (worse) than that of the final stepwise
model (range of 38.9 point decrease to 27.3 point increase).
As shown in Table 8, the RMSE of the best SOHGA
candidate was greater than 10 points lower for citalopram
(-38.9) but higher for DMAG (27.3) and olanzapine
(21.7). The absolute value of the MPE of the best SOHGA
Table 8 Mean prediction error (MPE) and root mean square error (RMSE) for the final stepwise model and the single-objective, hybrid genetic
algorithm (SOHGA) candidate model with lowest fitness function value
Compound Mean prediction error (MPE) Root mean square error (RMSE)
Final stepwise
model
Best SOHGA
candidate model
abs(MPESOHGA)
- abs(MPEstepwise)
Final stepwise
model
Best SOHGA
candidate model
RMSESOHGA
- RMSEstepwise
Citalopram 0.46 0.28 -0.18 92.2 53.3 -38.9
DMAG -5.49 -4.51 -0.98 1,167.8 1,195.1 27.3
Escitalopram -1.16 -1.06 -0.10 132.6 133.1 0.5
Olanzapine 0.52 -1.26 0.74 345.4 367.1 21.7
Perphenazine -0.19 -0.17 -0.02 14.9 15.1 0.2
Risperidone -0.34 0.81 0.47 116.9 116.5 -0.4
Ziprasidone 8.14 8.31 0.17 622.0 613.8 -8.2
Table 7 Values of the Akaike
information criterion (AIC),
Bayesian information criterion
(BIC), and pharmacokinetic
objective function value (OBV)
for the final stepwise model and
the single-objective, hybrid,
genetic algorithm (SOHGA)
candidate model with the lowest
fitness function value
Compound Final stepwise model Final SOHGA model AICSOHGA
- AICstepwise
Citalopram, IV BIC = 5,474.9 BIC = 5,457.8 -22.3
AIC = 5, 391.9 AIC = 5,369.6
OBV = 5,359.9 OBV = 5,335.6
DMAG, IV BIC = 9,942.3 BIC = 9,920.0 -22.3
AIC = 9,871.7 AIC = 9,849.4
OBV = 9,843.7 -OBV = 9,821.4
Escitalopram [21] BIC = 2,800.1 BIC = 2,783.4 -0.1
AIC = 2,737.7 AIC = 2,737.6
OBV = 2,707.1 OBV = 2,715.6
Olanzapine, oral [14] BIC = 10,413.8 BIC = 9,937.9 -470.5
AIC = 10,365.8 AIC = 9,895.3
OBV = 10,347.8 OBV = 9,879.3
Perphenazine, oral [15] BIC = 601.1 BIC = 604.4 -4.8
AIC = 560.7 AIC = 555.9
OBV = 540.7 OBV = 531.9
Risperidone, oral [16] BIC = 5,202.8 BIC = 4,934.9 -278.1
AIC = 5,131.1 AIC = 4,853.0
OBV = 5,103.1 OBV = 4,821.0
Ziprasidone, oral [17] BIC = 4,789.3 BIC = 4,784.8 -4.5
AIC = 4,763.2 AIC = 4,758.7
OBV = 4,751.2 OBV = 4,746.7
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candidate was a median of 0.02 point lower (improvement)
than that of the final stepwise model (range of 0.98 point
decrease to 0.74 point increase).
Models for clinical datasets, secondary outcomes—
model structure, convergence and covariance steps,
and parameters
The compartment structures between the final stepwise and
best SOHGA candidate agreed for six of the seven (86 %)
compounds with risperidone as the single exception (see
Appendix B). For the risperidone dataset, the best SOHGA
candidate used a two compartment model (ADVAN4)
whereas the final stepwise model used a one compartment
model (ADVAN2). Post hoc assessment of the best SO-
HGA candidate (ADVAN4) versus the same model with
ADVAN2 confirmed, by the likelihood ratio test, that the
two additional parameters (k23 and k32) in the best SO-
HGA candidate were statistically significant (DOBV =
146) at p \ 0.01.
The best SOHGA candidate model had successful con-
vergence and covariance steps for each compound
(Table 9). All final stepwise models also converged,
although the absorption rate constant (Ka) was fixed for
four compounds due to aid the convergence; the covariance
step was unsuccessful for two compounds.
Comparison of the inclusion of covariates between the
final stepwise and best SOHGA models had a kappa value
of 0.32 which implies fair agreement of the covariate
recognition (see Appendix B). The hybrid GA models
included 54 % (7 of 13) of covariates in the stepwise
models and the stepwise model included 30 % (7 of 23) of
covariates in the best-fitting candidate SOHGA models.
The inclusion of inter-individual and inter-occasion
variability between the final stepwise and hybrid SOHGA
models had a kappa value of 0.28 which implies fair
agreement. For stepwise model parameters with variability,
the SOHGA also included variability terms on 64 % (14 of
21) of the parameters while the stepwise models included
variability on 93 % (14 of 15) of parameters with these
terms in the best SOHGA candidate models.
The median percent difference in parameter values (see
Appendix C) between the final stepwise and best SOHGA
candidate models for a compound was 26.7 % (inter-
quartile range of 4.9–57.1 %).
Models for clinical dataset, Secondary analysis—best
SOHGA candidate model using FOCE with interaction
for the risperidone dataset
The SOHGA approach identified a best candidate model
that successfully converged for risperidone dataset using
FOCE with interaction (OBV = 4,738.7 and condition
number = 38). The best SOHGA candidate with FOCE
used a two compartment model with absorption
(ADVAN2/TRANS2) and a two compartment mixture for
clearance. The best SOHGA candidate using FOCE with
interaction included covariate effects of age, fluoxetine use,
sex, and weight on clearance and inter-individual vari-
ability of clearance and the volume of distribution.
Comparing the structure of models developed using
FOCE with interaction versus those using FO, the best
SOHGA candidate using the FOCE with interaction
method implemented the same compartment structure as
the final stepwise model using FO (one compartment) but a
different compartment structure than the best SOHGA
candidate using FO (two compartment). In addition, the
mixture model of the best SOHGA candidate using FOCE
with interaction (two components) is different from that the
final models that used FO (three components).
Table 9 Completion of convergence and covariance steps for the final stepwise model and the single-objective, hybrid genetic algorithm
(SOHGA) candidate model with lowest fitness function value
Convergence Covariance step (condition number)
Final manual stepwise
model
Best SOHGA
candidate
Final stepwise
model
Best SOHGA
candidate
Citalopram, IV Successful Successful Unsuccessful (N/A) Successful (2,830)
DMAG, IV Successful Successful Successful (20) Successful (25)
Escitalopram [21] Successful Successful Successful (39) Successful (9)
Olanzapine, oral [14] Required fixing Ka early in
model building process
Successful Successful (12) Successful (50)
Perphenazine, oral [15] Required fixing Ka early in
model building process
Successful Unsuccessful (N/A) Successful (212)
Risperidone, oral [16] Required fixing Ka early in
model building process
Successful Successful (61) Successful (1.17x106)
Ziprasidone, oral [17] Required fixing Ka early in
model building process
Successful Successful (3) Successful (5)
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Models for clinical datasets, post hoc analysis—best
SOHGA candidate models with condition number
penalty
Without a condition number penalty term in the fitness
function, the best SOHGA candidate had a condition
number [1,000 for two compounds (see Table 9): citalo-
pram (condition number = 2,830) and risperidone (condi-
tion number = 1.17 9 106). With a condition number
penalty term included in the SOHGA analysis, the condi-
tion numbers for the best candidate models were 426 and
134 for citalopram and risperidone, respectively. Both of
the post hoc best SOHGA candidates used the same com-
partment structure as the best models from the planned
analyses.
With a condition number penalty included in the SOHGA
analysis of the citalopram dataset, the AIC for the best
SOHGA candidate (5,389.6) was 2.3 points lower than that
of the final stepwise model and 20.0 points higher than that
of the best SOHGA candidate without a condition number
penalty. The best post hoc SOHGA candidate for citalopram
had a similar MPE (-0.19) to the final stepwise model but
the RMSE (52.2) was 40 points lower than that of the final
stepwise model. The best post hoc, SOHGA candidate
included covariate effects of sex on the central volume,
weight on the inter-compartment clearance, and weight on
the peripheral volume. This candidate also included inter-
individual variability terms on central volume, inter-com-
partment clearance, and peripheral volume.
With a condition number penalty included in the SOHGA
analysis of the risperidone dataset, the AIC for the best
SOHGA candidate (4,855.1) was 275.4 points lower than
that of the final stepwise model and 2.7 points higher than
that of the best SOHGA candidate without a condition
number penalty. The best post hoc SOHGA candidate for
risperidone had a similar MPE (-0.36) to the final stepwise
model but the RMSE (125.8) was 9.9 points higher than that
of the final stepwise model. The best post hoc, SOHGA
candidate used a three compartment mixture for clearance
and included covariate effects of age, paroxetine use, and
sex on clearance. This candidate also included inter-indi-
vidual variability terms on clearance, central volume, and
inter-compartment clearance.
Discussion
We hypothesized that a single-objective, hybrid genetic
algorithm (SOHGA) approach for selection of covariates
and function forms in pharmacokinetic model building
would accurately identify covariates, models, and appro-
priate initial estimates of model parameters with equal or
superior fits to clinical data versus a manual stepwise
method building approach. For covariate identification in a
simulated dataset, we found that a SOHGA with a 10 point
penalty per covariate correctly identified as many true
covariates as an automated stepwise covariate modeling
(three of four covariates) but with fewer spurious covariate
relationships (1 vs. 2 spurious covariates). When applied to
clinical datasets, we found that the best SOHGA candidate
models outperformed the final manual stepwise models by
at least 10 points in the AIC for four of seven compounds
with nominal differences for three compounds and 10 point
worse performance for none of the compounds. These
results are consistent with the finding of a previous single
compound pilot study in which the genetic algorithm
approach to pharmacokinetic model building resulted in a
better fit to clinical data than a stepwise modeling approach
[3].
For the fits to simulated data, as expected, models with
more stringent criteria for covariate incorporation had
fewer spurious covariates. Changing the p value for
exclusion from 0.05 to 0.01 in the automated SCM method
led to 1 fewer spurious covariates and increasing the point
penalty in the SOHGA from 3.84 to 10 points per covariate
led to 2 fewer spurious covariates. While it is possible that
a more stringent criteria for covariate incorporation could
lead to exclusion of true covariates, this was not this case in
this dataset as all automated SCM and SOHGA options
identified three of four true covariates. However, all auto-
mated SCM and SOHGA options failed to identify the
effect of body surface area on the volume of distribution.
This was unexpected because the change in volume due to
body surface area was expected to be equivalent to the
change due to gender and gender was identified as a sig-
nificant covariate by all automated approaches. It is pos-
sible that individual volumes of distribution happened to be
selected from the random distribution such that the effect
of body surface area was diminished from the expected
value.
The typical values of parameters estimated by the
automated SCM, Lasso, and SOHGA methods were all
similar to those of the true model. This suggests that the
SOHGA can accurately identify parameter values. How-
ever, this results is not generalizable based on a single
simulation study and does not imply that SOHGA param-
eter estimates will be accurate for all possible datasets and
model scenarios.
It is important to note that, although both the SCM and
SOHGA included the spurious covariate of height as a
predictor of volume rather than the true covariate of body-
surface area, the objective function values for these models
are lower than for the true model (3.3 points lower for
SOHGA and 10.1 points lower for SCM). This suggests
that, based on the change in objective function, both
methods selected the better covariate although it was not
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the true (used in the simulation model) covariate. The
correlation between height and body-surface area was high
(0.92) so the effect of height was likely due to its corre-
lation with body-surface area.
For the clinical datasets, the best SOHGA candidate
models of all seven compounds successfully converged
while the stepwise approach fixed the absorption rate
constant for four compounds to achieve convergence. In
addition, the SOHGA approach identified a candidate
model for the risperidone which successfully converged
using the FOCE with interaction approach which the
stepwise approach did not. This suggests that, the SOHGA
approach identified regions of solution space that con-
verged in which the stepwise approach did not. This is most
likely because the SOHGA approach can search the error,
covariate, and initial estimate space for regions that con-
verge and select candidate models from within those
regions. Fixing the absorption rate constant in the stepwise
approach restricted the models to a particular region of
solution space. The improvements in AIC with the SOHGA
approach to modeling olanzapine (DAIC = -468.5) is
likely due to the extra degree of modeling freedom pro-
vided by the absorption rate model parameter which the
stepwise approach fixed based on literature values. This
parameter was fixed early in the manual model building
process due to a failure of the model to converge and was
not revisited after subsequent changes were made to the
model. This inability to estimate a specific parameter at one
point in the modeling process but have the parameter be
identifiable when other features are present is an example
of the interdependence of model features and is similar to
the documented interaction between compartments, vari-
ance terms, and covariates [2]. In contrast, the SOHGA
method revisits and retests such a ‘‘decision’’ multiple
times and in different combinations with other model fea-
tures. This reduces the risk of missing important features as
well as making it more likely to select the numerically
optimal combination of features.
The lower AIC with the SOHGA approach to modeling
citalopram (DAIC = -22.3) is most likely due to the
inclusion of additional covariate terms in the models. The
best SOHGA candidate model for citalopram captures two
of the three covariates of the stepwise model along with
four additional covariate relationships and nearly identical
the error structures between the two models. These model
improvements suggest that the SOHGA identified interac-
tions between model components that were not recognized
by the stepwise approach. The lower AIC for risperidone
with the SOHGA (DAIC = -278.1) is likely a combina-
tion variable absorption rate and additional covariates; the
best SOHGA candidate model for risperidone included four
covariate terms versus zero for the final stepwise model
although the best SOHGA model has one less mixture
compartment for clearance. Finally, the lower AIC for
DMAG with the SOHGA (DAIC = -22.3) is most likely
due to application of inter-occasion variability on clearance
as opposed to the central volume.
However, the minor differences RMSE between the final
stepwise models and best SOHGA candidates suggests that
the improvements seen in AIC and the model description of
data may not necessarily translate to benefits in predictive
value.
Although a condition number penalty was not included
in the SOHGA fitness function, the best SOHGA candidate
model had condition numbers \1,000 for all compounds
except for citalopram and risperidone. This suggests that
the data was capable of supporting the best SOHGA can-
didate models except for those of citalopram and risperi-
done. However, with the addition of the condition number
penalty, the SOHGA approach identified candidate models
for citalopram and risperidone with condition numbers
\1,000.
Over the seven compounds, the best SOHGA candidate
models included more covariates than the stepwise approach
(23 vs. 13) while including fewer variability terms (15 vs.
22); the SOHGA tended to describe variability with covari-
ates rather than unknown variability relative to the stepwise
approach. This was despite the penalty for fixed effect
(THETA) and inter-individual variability (OMEGA) terms
being equal (10 points). However, the best SOHGA candi-
date models did not include half of the covariates identified
by the stepwise approach. This raises concerns about whe-
ther these covariates are an artifact of the model building
approach [2].
It should be noted that the criteria for inclusion of a
covariate in the stepwise regression was 3.84, based on the
likelihood ratio test while the criteria for inclusion in the
SOHGA approach was 10 points. This higher threshold for
inclusion of a covariate effect in the SOHGA may be
responsible for the lack of inclusion of other covariate
relationships that were found using the stepwise regression
approach. However, as demonstrated in the simulated
dataset, this higher threshold for inclusion also provides
some protection from inclusion of spurious covariates.
The 26.7 % median change in pharmacokinetic model
parameters between the final stepwise and best SOHGA
candidate models suggests that the model parameters are
generally comparable. Much of this difference may be due
to the fixed absorption rate constants in the final stepwise
models and the differing covariate, variability, and error
structures between the final stepwise and best SOHGA
candidate models.
The strengths of this study are that the SOHGA method
was tested on multiple compounds with data coming from
multiple sites. The SOHGA was also applied over various
conditions as the data for different compounds covered
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various time scales (months for SZ patients, weeks for AD
patients, and hours for citalopram and DMAG), both oral
and intravenous administration, and degrees of data and
patient sample sizes and sparseness.
This study has several limitations. First, all models were
either one-, two-, or three-compartment models, so the
generalizability of the effectiveness of SOHGA approach
to other model structures is uncertain. However, the
SOHGA approach is entirely general and can be used for
models described by ordinary differential equations, mix-
ture models (such as the mixture model on clearance of
risperidone implemented in this study), and odd type data.
Another limitation is that the study involved mostly
schizophrenia and Alzheimer’s patients and medications.
The extent to which these results are generalizable to other
medications and patients is uncertain.
There are also general limitations to using a genetic
algorithm. While genetic algorithms quickly converge to
‘‘good’’ regions of the solution space, convergence to the
‘‘best’’ local and global solutions is much slower due to the
random nature of the method. The hybrid technique aids in
identifying local optima but convergence to the global opti-
mum within the simulation cannot be guaranteed. Another
consequence is that the genetic algorithm approach could
result in multiple, equally valid solutions from different
regions of the solution space. If these regions have different
characteristics, it would be difficult to draw conclusions
about covariates and model structure from strictly numerical
results. This emphasizes the important role for the modelers
in assessing biological plausibility, graphic diagnostics, and
clinical importance of model features. While genetic algo-
rithms can identify globally optimal solutions, the robustness
of these solutions was not considered here. Finally, genetic
algorithms are most efficient when the candidate models are
evaluated in parallel rather than series so multiple core
computers are recommended. The SOHGA models presented
here took 6–150 h on a 24 processor computer server. More
computational power, as is readily available with cloud
computing, grid computing, or other shared resources meth-
ods, would decrease the run times. However, given this
modest hardware configuration and the weeks to months of
time to develop a model using manual approaches, the
computational costs are not overly burdensome.
Also, the use of a single objective function can poten-
tially introduce biases due to the ad hoc weighting. In this
analysis, a ten point penalty for each model parameter was
chosen based on the ‘‘Sheiner criteria.’’ (Lewis Sheiner,
personal communication with one of the authors (MS). Dr.
Sheiner explained that he often used 10 points as his cri-
teria to include a parameter to correct for multiple com-
parisons, and because he rarely could see any difference in
plots if the change in OBV was less than 10 points.) A
smaller penalty would likely lead to more covariates in the
model (and better overall fit but with a higher chance of
spurious covariates) and a higher penalty would lead to
inclusion of fewer covariates (and worse overall fit but with
a lower chance of spurious covariates). The large penalty
assigned for failure of convergence and failure of the
covariance step (and the condition number, when imple-
mented) was to give a high priority to these outcomes, as
some modelers feel strongly that a successful covariance
step is a necessary (but not sufficient) condition for a
‘‘final’’ model. A potential solution to these ad hoc pen-
alties is the use of a multi objective function—with a
dimension for each penalty term in the single objective
algorithm—would yield a front of non-dominated optimal
solutions [9]. However, both of these approaches (single
objective and multi objective optimization) to the covari-
ance step rely on a pass/fail criterion. Information from the
covariance step output can often be used to understand
additional opportunities to improve the model. However,
hypothesis generation is the responsibility of the user and
additional hypotheses to improve the model can be used to
expand the search space on subsequent SOHGA analyses
or by traditional forward addition/backward elimination.
The SOHGA algorithm presented here also does not
consider the feasibility of or prior knowledge about model
parameters. However, these factors could be included by
introducing additional weighting in the fitness function.
That is, an additional bonus is applied for covariates that
the modeler feels should be included (e.g., a weight effect
on volume of distribution) and a penalty is imposed for
undesired interactions (e.g., having both body-mass index
and weight modify a variable). While this weighting cannot
guarantee the inclusion/exclusion of model parameters, it
does shift the likelihood based on the modelers input.
Finally, using the SOHGA approach may result in the
temptation to inadequately explore model parameter rela-
tionships and potential bias using graphics in pharmacoki-
netic model building. That is, the user may be tempted to
spend less time looking at diagnostic plots and generating
biologically sound hypotheses. The SOHGA cannot replace
thorough examination of the data and hypothesis generation;
SOHGA only automates the actual search part of the step-
wise regression (e.g., construction of control files, running
the model, quantifying results and construction of new
control files). All intellectual input into the model selection
process—the examination of graphics and hypothesis gen-
eration—remains the responsibility of the modeler. In a
manner similar to traditional stepwise analysis, the best
models from a SOHGA analysis can be examined using
traditional diagnostic plots or other means and additional
hypotheses generated to explain observed bias. All models
run by SOHGA are available and the interface makes in
convenient to identify models with desirable characteristics
such as lower value of the objective function or parsimony.
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The search space can then be expanded to include these new
hypotheses before SOHGA is run again.
Further, these results do not suggest that SOHGA, or any
automated search algorithm, is likely to provide the final
model for an analysis. A more practical approach to arriving
at the ‘‘final’’ model may be that SOHGA would provide
something comparable to initial parameter estimates for non-
linear regression. That is, it is common practice to start a
model building exercise with a trivial model (e.g., one
compartment, no covariates, no inter-occasion variability, no
mixture models, etc.), but it is likely that, while probably not
the final model, a model from SOHGA will be closer to the
true global minimum in the search space than the traditional
trivial model. Given what is known about the failure of the
assumption of monotonicity of the model search space [2],
having a better starting place in the search space may result in
a higher likelihood of finding the global minimum using
traditional forward addition and backward elimination
model building methods rather than a local minimum. A
likely use scenario might be that the user assesses a number
of the ‘‘best’’ models selected by SOHGA (e.g., those with
low OBV, the most parsimonious, etc.) and the strengths and
biases of each model can be assessed using standard diag-
nostic graphics and methods as well as biological plausibil-
ity. The features from different models can be recombined
based on these assessments. As is the case for non-linear
regression, the number of iterations may be fewer if a better
starting point is provided.
It is likely that, initially at least, the SOHGA approach is
best suited for compounds in which the biology is fairly well
understood, and not for highly exploratory analyses. There
are two reasons for this. First, experience suggests that
hypotheses in poorly understood compounds typically come
in small numbers—often one at a time—after examination of
plots. The SOHGA approach requires that many (although
not all) hypotheses be available initially. As discussed above,
it is reasonable to perform a SOHGA search, examine the
results and conclude that additional hypotheses are required,
and then perform another SOHGA search with an expanded
search space. But, if the drug is very poorly understood, few
hypotheses may be available prior to the start of the model
building. As a result, a process of running SOHGA with only
a few hypotheses, examining the results, and generating new
hypotheses may become even more tedious than step wise
regression. Second, SOHGA is very computationally inten-
sive. Complex model often require ordinary differential
equation solutions, which can be very computationally
intensive as well, making SOHGA impractical.
In conclusion, our results suggest that a single-objective,
hybrid genetic algorithm can be used to fit pharmacokinetic
model structures and covariates to data. This approach
could be used either stand-alone or to identify regions of
the solution space that could be explored further manually.
Further additions to the genetic algorithm could include
other objective measures of model quality and multi-
objective optimization. Genetic algorithms provide a sys-
tematic way to identify covariates, interactions, initial
parameter estimates, and the model structure for pharma-
cokinetic models accounting for interactions among model
components that may otherwise be difficult to identify.
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Appendix
For Appendices A, B, and C, see Tables 10, 11, and 12,
respectively.
Table 10 Correlation matrix of simulated covariates and the NONMEM control file used for generation of simulated patient dataset
BMI HT CR AGE WT BSA CRCL CV1 CV2 CV3 CV4
BMI 1.000
HT 0.072 1.000
CR -0.025 -0.059 1.000
AGE -0.065 -0.059 0.086 1.000
WT 0.571 -0.041 -0.070 -0.071 1.000
BSA 0.441 0.923 -0.066 -0.063 0.985 1.000
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Table 10 continued
BMI HT CR AGE WT BSA CRCL CV1 CV2 CV3 CV4
CRCL 0.476 0.794 -0.368 -0.255 0.916 0.906 1.000
CV1 0.058 -0.078 0.072 -0.010 -0.023 -0.043 -0.050 1.000
CV2 0.134 0.000 0.012 0.041 0.070 0.049 0.057 0.010 1.000
CV3 -0.048 -0.061 0.029 -0.044 -0.073 -0.073 -0.071 0.019 0.000 1.000
CV4 -0.008 -0.030 0.012 0.032 -0.026 -0.032 -0.048 0.024 0.020 -0.026 1.000
BMI body-mass index, HT height, CR creatinine, AGE patient age, WT weight, BSA body-surface area, CRCL creatinine clearance, CV1 first
unrelated covariate, CV2 second unrelated covariate, CV3 third unrelated covariate, CV4 fourth unrelated covariate
$PROBLEM SIM MODEL
$INPUT ID TIME AMT DV BMI HT CR AGE GEN WT BSA GFR CV1 CV2 CV3 CV4
$DATA DATA.PRN
$SUBROUTINE ADVAN1 TRANS2
$PK
CBMI = (BMI-26.29)/4.093
CHT = (HT-1.586)/0.2
CCR = (CR-0.985)/0117
CAGE = (AGE-38.81)/8.189
CWT = (WT-67.4)/21.2
CBSA = (BSA-1.713)/0.363
CGFR = (GFR-91.4)/37.9
CCV1 = (CV1-101.6)/30.7
CCV2 = (CV2-11)/4.33
CCV3 = (CV3-1.01)/0.209
CCV4 = (CV4-0.098)/0.0198
TVCL = THETA(1)*EXP(THETA(2)*BMI)*EXP(THETA(3)*GFR)
CL = TVCL*EXP(ETA(1))
TVV = THETA(4)*EXP(THETA(5)*BSA)*EXP((1-GEN)*THETA(6))
V = TVV*EXP(ETA(2))
S1 = V
$ERROR
Y = F*EXP(EPS(1)) ?EPS(2)
IPRED = F*EXP(EPS(1)) ?EPS(2); individual-specific prediction
$THETA (0,0.1); BASELINE CL
$THETA (0,0.04); BMI ON CL
$THETA (0,0.01); crcl oncl
$THETA (0,1); baseline volume
$THETA (0,0.3); bsa on V
$THETA (0,0.3); GEN ON V
$OMEGA BLOCK(2)
.2
0.05 .2
$SIGMA 0.1 0.001
$SIMULATION (12345) ONLYSIM
$TABLE ID TIME AMT IPRED BMI HT CR AGE GEN WT BSA GFR CV1 CV2 CV3 CV4
NOPRINT FILE = OUT.DAT ONEHEADER
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Table 11 Model structures and covariates of the final stepwise model and the single-objective, hybrid genetic algorithm (SOHGA) candidate
model with the lowest fitness function value
Compounds Covariates in stepwise model
(abbreviation of function forma)
Covariates in the best SOHGA candidate
model (abbreviation of function forma)
Citalopram, IV ADVAN3, TRANS4 (2 compartments) ADVAN3, TRANS4 (2 compartments)
Clearance—TVCL Weight (pow) –
Inter-individual variability—g(CL) – –
Central volume—TVV1 Sex (add) Sex (exp), body-mass index (exp)
Inter-individual variability—g(V1) Exponential Exponential
Inter-comp clearance—TVQ Fat mass (exp) Fat mass (prop), fat-free mass (exp)
Inter-individual variability—g(Q) Exponential Exponential
Peripheral volume—TVV2 Weight (pow) Fat (exp), fat-free mass (exp)
Inter-individual variability—g(V2) Exponential Exponential
Residual variability—e(1) and e(2) Combined Proportional
DMAG, IV ADVAN11, TRANS4 (3 compartments) ADVAN11, TRANS4 (three
compartments)
Clearance—TVCL – Sex (exp)
Inter-individual variability—g(CL) Exponential Exponential
Inter-occasion variability—g(OCC,CL) – Exponential
First comp clearance—TVQ1 – –
Inter-individual variability—g(Q1) – –
Inter-occasion variability—g(OCC,Q1) Exponential Exponential
Second comp clearance—TVQ2 – –
Inter-patient variability—g(Q2) Exponential –
Central volume—TVV1 – –
Inter-individual variability—g(V1) Exponential Exponential
Inter-occasion variability—g(OCC,V1) Exponential –
Peripheral volume—TVV2 – –
Inter-individual variability—g(V2) Exponential Exponential
Third volume—TVV3 – –
Inter-patient variability—g(V3) Exponential –
Residual variability—e(1) and e(2) Proportional Combined
Escitalopram, oral ADVAN2, TRANS2 [17] (one
compartment with absorption)
ADVAN2, TRANS2 (one compartment
with absorption)
Clearance—TVCL Age (pow), genotype (add), weight (pow) Age (pow), site (add)
Inter-individual variability—g(CL) Exponential Exponential
Volume of distribution—TVV Body mass index (pow) Body mass index (pow)
Inter-individual variability—g(V) Exponential Exponential
Absorption rate constant—TVKA – –
Inter-individual variability—g(KA) Exponential –
Residual variability—e(1) and e(2) Proportional Combined
Olanzapine, oral ADVAN2, TRANS2 [10] (one
compartment with absorption)
ADVAN2, TRANS2 (one compartment
with absorption)
Clearance—TVCL Race (add), sex (add), smoking status
(add)
Age (add), sex (add)
Inter-individual variability—g(CL) Exponential Exponential
Volume of distribution—TVV – –
Inter-individual variability—g(V) Exponential –
Absorption rate constant—TVKA Unstable: fixed based on literature –
Inter-individual variability—g(KA) – –
Residual variability—e(1) and e(2) Additive Combined
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Table 11 continued
Compounds Covariates in stepwise model
(abbreviation of function forma)
Covariates in the best SOHGA candidate
model (abbreviation of function forma)
Perphenazine, oral ADVAN2, TRANS2 [11] (one
compartment with absorption)
ADVAN2, TRANS2 (one compartment
with absorption)
Clearance—TVCL Race (add), smoking status (add) Fluoxetine use (exp), number of cigarettes
per day (exp), race (exp), smoking
status (prop)
Inter-individual variability—g(CL) Exponential Exponential
Volume of distribution—TVV – Age (exp), sex(exp), and smoking status
(prop)
Inter-individual variability—g(V) Exponential –
Absorption rate—TVKA Unstable: fixed based on literature –
Inter-individual variability—g(KA) Exponential –
Residual variability—e(1) and e(2) Proportional Proportional
Risperidone, oral ADVAN2, TRANS2 with three
component clearance mixture [12] (one
compartment with absorption)
ADVAN4, TRANS4 with three
component mixture on clearance (two
compartment with absorption)
Clearance—TVCL – Age (exp), fluoxetine use (exp),
paroxetine use (exp), race (exp)
Inter-individual variability—g(CL) Exponential Exponential
Volume of distribution—TVV – –
Inter-individual variability—g(V) Exponential –
Central volume—TVV1 – –
Inter-individual variability—g(V1) – Exponential
Inter-comp clearance—TVQ – –
Inter-individual variability—g(Q) – –
Peripheral volume—TVV2 – –
Inter-individual variability—g(V2) – –
Absorption rate constant—TVKA Fixed based on literature –
Inter-individual variability—g(KA) Exponential –
Residual variability—e(1) and e(2) Combined Proportional
Ziprasidone, oral ADVAN2, TRANS2 [13] (one
compartment with absorption)
ADVAN2, TRANS2 (one compartment
with absorption)
Clearance—TVCL – –
Inter-individual variability—g(CL) Exponential Exponential
Volume of distribution—TVV – –
Inter-individual variability—g(V) Exponential Exponential
Absorption rate constant—TVKA Unstable: fixed based on literature –
Inter-individual variability—g(KA) – –
Residual variability—e(1) and e(2) Proportional Proportional
a Abbreviations for functional forms include: add additive, prop proportional, exp exponential, pow power-law
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Table 12 Typical parameter values, inter-individual and inter-occasion variability, and residual error of the final stepwise model and the single-
objective, hybrid genetic algorithm (SOHGA) candidate model with the lowest fitness function value
Compound Parameter estimatesa,b,c (relative standard error)
Final stepwise model Best SOHGA candidate
model
Citalopram, IV—two compartment
Clearance (L/h)—TVCL 7.11 (NA) 1.22 (5.3 %)
Inter-individual variability—xCL of gCL – –
Inter-comp clearance (L/h)—TVQ 64.4 (NA) 6.26 (19.0 %)
Inter-individual variability—xQ of gQ 48.5 % (NA) 35.5 % (19.0 %)
Central volume (L)—TVV1 2.87 (NA) 82.1 (17.7 %)
Inter-individual variability—xV1 of gV1 12.2 % (NA) 46.2 % (15.5 %)
Peripheral volume (L)—TVV2 1,510 (NA) 205 (12.6 %)
Inter-individual variability—xV2 of gV2 22.6 % (NA) 25.4 % (12.5 %)
Residual variability—r of e rprop = 14.6 % (NA) and rprop = 10.5 % (28.0 %)
radd = 0.0 lg/L (NA) –
DMAG—three compartment
Clearance (L/h)—TVCL 8.4 (11.2 %) 9.28 (7.9 %)
Inter-patient variability—xCL of gCL 53.8 % (22.9 %) 22.1 % (29.1 %)
Inter-occasion variability—xCL of gOCC,CL – 8.3 % (38.6 %)
First inter-compartment clearance (L/h)—TVQ1 85.1 (9.6 %) 81.0 (8.9 %)
Inter-patient variability—xQ1 of gQ1 – –
Inter-occasion variability—xQ1 of gOCC,Q1 32.6 % (37.2 %) 14.0 % (32.7 %)
Second inter-compartment clearance (L/h)—TVQ2 11.6 (13.1 %) 8.21 (17.4 %)
Inter-patient variability—xQ2 of gQ2 75.8 % (32.0 %) –
First compartment volume (L)—TVV1 27.4 (11.7 %) 28.1 (12.9 %)
Inter-patient variability—xV1 of gV1 33.0 % (111.9 %) 39.7 % (24.5 %)
Inter-occasion variability 59.7 % (31.2 %) –
Second compartment volume (L)—TVV2 66.4 (10.1 %) 77.9 (11.4 %)
Inter-patient variability—xV2 of gV2 50.7 % (23.7 %) 42.3 % (24.8 %)
Third compartment volume (L)—TVV3 142 (13.5 %) 86.4 (8.5 %)
Inter-patient variability—xV3 of gV3 67.5 % (37.3 %) –
Residual variability—r of e rprop = 16.1 % (2.7 %) rprop = 2.1 % (13.2 %) and
– radd = 24.7 lg/L (69.6 %)
Escitalopram, oral—one compartment with absorption
Clearance (L/h)—TVCL – 25.5 (5.3 %)
Extensive metabolizer 26 (7.20 %) –
Poor metabolizer 19.8 (8.50 %) –
Missing metabolizer information 21.5 (7.80 %) –
Inter-individual variability—xCL of gCL 48.5 % (15.1 %) 48.8 % (12.3 %)
Volume of distribution (L)—TVV 947 (10.2 %) 874 (11.8 %)
Inter-individual variability—xV of gV 62.0 % (40.3 %) 59.4 % (32.6 %)
Absorption (1/h)—TVKA 0.8 (NA) 0.594 (23.1 %)
Inter-individual variability—xKA of gKA 78.9 % (87.0 %) –
Residual variability—r of e rprop = 28.9 % (8.8 %) rprop = 28.8 % (11.1 %)
and
– radd = 70.4 lg/L (131 %)
Olanzapine, oral—one compartment with absorption
Clearance (L/h)—TVCL 16.1 (7.3 %) 21.1 (15.5 %)
Inter-individual variability—xCL of gCL 68 % 64.7 % (17.2 %)
Volume of distribution (L)—TVV 2,150 (26.0 %) 4,130 (48.9 %)
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Table 12 continued
Compound Parameter estimatesa,b,c (relative standard error)
Final stepwise model Best SOHGA candidate
model
Inter-individual variability—xV of gV 86 % –
Absorption rate constant (1/h)—TVKA Fixed at 0.5 0.773 (70.4 %)
Inter-individual variability—xKA of gKA – –
Residual variability—r of e – rprop = 37.7 % (14.5 %)
and radd = 275 lg/L
(50.9 %)
radd = 212 lg/L (1.7 %)
Perphenazine, oral—one compartment with absorption (95 % CI from bootstrapping)
Clearance (L/h)—TVCL 483 354 (12.3 %)
Inter-individual variability—xCL of gCL 79.3 % (68.1 - 87.4 %) 78.8 % (11.4 %)
Volume of distribution (L)—TVV 18,200 (13,865 - 65,795) 1.10x107 (172 %)
Inter-individual variability—xV of gV 78.5 % (20 - 120 %) –
Absorption rate constant (1/h)—TVKA Fixed at 1.6 0.859 (80.7 %)
Inter-individual variability—xKA of gKA 336.1 % (0.35 - 518 %) –
Residual variability—r of e rprop = 37.4 % (33.3 - 41.0 %) rprop = 37.1 % (10.5 %)
Risperidone, oral—one compartment with absorption 3 component mixture for clearance 3 component mixture for
clearance
Percent of subjects who were poor metabolizers 41.2 % (8.1 %) 22.4 % (4.4 %)
Percent of subjects who were extensive metabolizers 52.4 % (6.2 %) 41.4 % (8.6 %)
Clearance (L/h)—TVCL – –
Poor metabolizer 12.9 (6.5 %) 12.4 (8.5 %)
Intermediate metabolizer Fixed at 36 34.9 (8.9 %)
Extensive metabolizer 65.4 (9.9 %) 122 (11.5 %)
Inter-individual variability—xCL of gCL – 7.3 % (32.2 %)
Poor metabolizer 95.9 % (39.5 %) –
Intermediate metabolizer NA (NA) –
Extensive metabolizer 56.6 % (16.8 %) –
Volume of distribution (L)—TVV 444 (17.8 %) –
Inter-individual variability—xV of gV 36.1 % (24.4 %) –
Central volume—TVV1 – 96.6 (31.2 %)
Inter-individual variability—g(V1) – 478 % (46.4 %)
Inter-comp clearance—TVQ – 27.1 (29.9 %)
Inter-individual variability—g(Q) – –
Peripheral volume—TVV2 – 1.31x1010 (1,000 %)
Inter-individual variability—g(V2) – –
Absorption rate constant (1/h)—TVKA Fixed at 1.7 0.184.(21.1 %)
Inter-individual variability—xKA of gKA 53.7 % (89.3 %) –
Residual variability—r of e rprop = 63.9 % (12.5 %) and rprop = .39.8 % (9.3 %)
radd = 4.29 lg/L (104.9 lg/L) –
Ziprasidone, oral—one compartment with absorption
Clearance (L/h)—TVCL 122 (9 %) 126 (9.0 %)
Inter-individual variability—xCL of gCL 64.8 % (25 %) 69.0 % (21.4 %)
Volume of distribution (L)—TVV 1,060 (19 %) 1,030 (12.4 %)
Inter-individual variability—xV of gV 104.4 % (27 %) 114 % (16.0 %)
Absorption rate constant (1/h)—TVKA Fixed at 0.5 0.424 (5.8 %)
Inter-individual variability—xKA of gKA – –
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Table 12 continued
Compound Parameter estimatesa,b,c (relative standard error)
Final stepwise model Best SOHGA candidate
model
Residual variability—r of e rprop = 65.5 % (8 %) rprop = 65.1 % (8.3 %)
a Parameter estimates denoted by ‘‘–’’ were not calculated and standard errors denoted by ‘‘NA’’ are not available because the covariance matrix
did not converge
b The reported inter-individual variability value is the standard deviation (x) of the random inter-individual variability variable (g), which is a
normal distribution with near zero mean
c The reported residual variability value is the standard deviation (r) of the residual variability variable (e), which is a normal distribution with
near zero mean
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